US FDA Grants Qualified Infectious Disease Product Designation to Venus Remedies
This breakthrough from Venus Medicine Research Centre has captured national attention, with coverage in The Economic Times, Business Standard, MoneyControl, Express Pharma, and more—a proud moment that puts Indian pharma innovation on the global map. "This milestone reflects our commitment to developing safer, life-saving therapies for global health challenges.” — Saransh Chaudhary, Chief Executive Officer ( Venus Medicine Re
Venus Remedies’ novel polymyxin B formulation, VRP-034, has been granted QIDP status by the US FDA—a major breakthrough in combating antimicrobial resistance. Developed with our proprietary Renal Guard technology, VRP-034 reduces nephrotoxicity by up to 70% while maintaining efficacy against drug-resistant infections.
VRP-034: Redefining Safety in Critical Care
Our
latest innovation, VRP-034, has earned QIDP status from the US FDA—a
game-changing step in the fight against antimicrobial resistance.
Engineered with Renal Guard technology, it cuts kidney toxicity by up to
70% while staying powerfully effective against drug-resistant
infections.
This breakthrough from Venus Medicine Research Centre has
captured national attention, with coverage in The Economic Times,
Business Standard, MoneyControl, Express Pharma, and more—a proud moment
that puts Indian pharma innovation on the global map. "This milestone
reflects our commitment to developing safer, life-saving therapies for
global health challenges.” — Saransh Chaudhary, Chief Executive Officer (
Venus Medicine Research Centre)
